Replies to post #32380 on RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Thanks Neuro. BTW, any thoughts on Cortex's SA and RD indications being part of the same deal?

I've been thinking that the liklihood of the two indications being linked into a single deal has grown, since - 1) Varney doesn't have much negotiating leverage, and - 2) he realistically can't include CX-1739 in a deal, so he may have to 'toss in' extra deal sweeteners, like SA.

Any thoughts on the liklihood that the RD partner from last year is still around, or is it more likely that current negotiations are with someone new?


Thanks.

[gfp927z]

Neuro, Any thoughts on Silenor's chances for approval in Insomnia? I see it's gotten several CRL/complete response letters already, with the FDA saying it lacked robustness and would also need an REMS included, but just wondering if it still might have a chance?

If approved, I wonder what the commercial potential might be?

The drug, doxepin, is already approved for Depression (a tricyclic, Sinequan) and is available as a generic, and is already prescribed off label for insomnia. Somaxon is looking for approval for an ultra low dose (~5 mg range), vrs the usual 50 mg, 100 mg or more for Depression.

Thanks for any insights.